{
  "folder": "IC-330",
  "content": "{{knowledge objective\n|Identifiant=OIC-330-08-A\n|Item_parent=Prescription and monitoring of the most common classes of medicines in adults and children, excluding anti-infectives (see item 177). Knowing the correct use of the main therapeutic classes.\n|Item_parent_short=Prescribing and monitoring the most common classes of medicines for adults and children, excluding anti-infectives (see item 177). Knowing the correct use of the main therapeutic classes.\n|Rank=A\n|Title=Oral anticoagulants (anti-vitamin K (AVK) and direct oral anticoagulants (AOD)): mechanisms of action, indications, side-effects, drug interactions, monitoring procedures and main causes of failure.\n|Description=Knowing the mechanisms of action\n|Rubric=Management\n|Contributors=Sabine Mainbourg,Laurent Bertoletti,Jean-Christophe Lega\n|Order=8}}\n\n==Mechanisms of action==\n<br />\n{| class=\"wikitable\"\n|'''Molecules'''\n|'''Action'''\n|'''Action time''''\n|'''Mechanism of action'''\n|-\n|Apixaban, rivaroxaban\n|Direct\n|1 to 2 hours\n|Factor Xa inhibition\n|-\n|Dabigatran\n|Direct\n|1 to 2 hours\n|Thrombin inhibition\n|-\n|Acenocoumarol, fluidione, warfarin\n|Indirect\n|2 to 3 days\n|Inhibition of carboxylation of vitamin K-dependent factors (''p'''rothrombin II, '''p'''roconvertin VII, haemophilic factor '''B''' IX, factor '''S'''tuart X).\n|}\n\n==Indications==\n{| class=\"wikitable\"\n|'''Molecules'''\n|'''Indications AMM''''\n|'''Non-indication/counter-indication'''\n|-\n|'''Apixaban, rivaroxaban''''\n|Prevention of venous thromboembolism in planned hip or knee surgery.\n\nPulmonary embolism, proximal deep vein thrombosis\n\nNon-valvular atrial fibrillation\n<br />Atrial fibrillation\n|Atrial fibrillation on mitral stenosis\n\nMechanical valve\n\nIntra-abdominal venous thrombosis\n\nVenous thrombosis of the upper limbs\n\nArterial thrombosis\n\nSAPL\n\nRenal insufficiency (GFR <30 mL/min), hepatocellular insufficiency, known haemorrhage or high risk of haemorrhage\n|-\n|Dabigatran\n|Prevention of venous thromboembolism in scheduled hip or knee surgery\n\nNon-valvular atrial fibrillation\n<br />Pulmonary embolism\n|Pulmonary embolism, proximal deep vein thrombosis\n\nAtrial fibrillation in mitral stenosis\n\nMechanical valve\n\nDistal venous thrombosis\n\nIntra-abdominal venous thrombosis\n\nVenous thrombosis of the upper limbs\n\nArterial thrombosis\n\nSAPL\n\nRenal insufficiency (GFR <30 mL/min), hepatocellular insufficiency, known haemorrhage or high risk of haemorrhage\n|-\n|'''Coumarinics''''\n\nAcenocoumarol, warfarin\n\n'''Indane-diones'''\n\nFluindione\n\n\nIn practice, only warfarin is used as a first-line treatment (immunoallergic risk of fluindione, short half-life of acenocoumarol).\n|Emboligenic heart disease, including AF, thrombo-embolic complications of MI and mechanical valves.\n\nPulmonary embolism and/or proximal deep vein thrombosis, as a relay to heparins\n\nFor use (off-label) for any arterial or venous thrombosis as a replacement for heparins in cases where AODs are contraindicated.\n|contraindicated in cases of severe hepatic insufficiency\n|}\n\n==Undesirable effects==\n\n===For all molecules===\n\n*Bleeding, any site possible\n\n===Specific to coumarins===\n\n*Gastrointestinal intolerances (gastralgia, vomiting, diarrhoea)\n\n===Preferred to Indo-Diones===\n\n*Immunological reaction (tubulointerstitial nephritis, rash, fever, hepatitis, aplasia)\n\n===Specific to AOD===\n\n*Hepatitis\n*thrombocytopenia\n*Hypersensitivity including rash\n\n===Specific to rivaroxaban===\n\n*Agranulocytosis\n\n===Specific to apixaban===\n\n*Alopecia\n\n===Specific to dabigatran===\n\n*Digestive disorders\n\n==Drug interactions==\n{| class=\"wikitable\"\n|'''Molecules'''\n|'''Pharmacodynamic interactions'''\n|'''Pharmacokinetic interactions'''\n|'''Comments'''\n|-\n|Apixaban\n|'''Major'''\n\nHeparins\n\nFibrinolytics\n\nOther AOD, AVK\n\n'''No major'''\n\nAnti-aggregants\n\nNSAIDS\n\nSelective serotonin reuptake inhibitors\n\nCorticosteroids (ulcers, vascular fragility)\n|CYP450 and P-glycoprotein inhibitors\n\nAzoles, protease inhibitors, erythromycin, clarithromycin, amiodarone, quinidine, naproxen\n\nCYP450 and P-glycoprotein inducers\n\nRifampicin, anticomitic drugs (phenytoin, phenobarbital, carbamazepine), St. John's wort\n|\n|-\n|Rivaroxaban\n|''Major'''\n\nHeparins\n\nFibrinolytics\n\nOther AOD, AVK\n\n'''No major'''\n\nAnti-aggregants\n\nNSAIDS\n\nSelective serotonin reuptake inhibitors\n\nCorticosteroids (ulcers, vascular fragility)\n|CYP450 and P-glycoprotein inhibitors\n\nAzoles, protease inhibitors, erythromycin, clarithromycin, amiodarone, quinidine, naproxen\n\nCYP450 and P-glycoprotein inducers\n\nRifampicin, anticomitic drugs (phenytoin, phenobarbital, carbamazepine), St. John's wort\n|\n|-\n|Diabigatran\n|''Major'''\n\nHeparins\n\nFibrinolytics\n\nOther AOD, AVK\n\n'''No major'''\n\nAnti-aggregants\n\nNSAIDS\n\nSelective serotonin reuptake inhibitors\n\nCorticosteroids (ulcers, vascular fragility)\n|P-glycoprotein inhibitors\n\nAmiodarone, verapamil, quidinie, tacrolimus, erythromycin, clarythromycin, naproxen,\n\nP-glycoprotein inducers\n\nRifampicin, anticomitic drugs (phenytoin, phenobarbital, carbamazepine), St. John's wort\n|\n|-\n|AVK\n|'''Major'''\n\nHeparins\n\nFibrinolytics\n\nAOD\n\n'''No major'''\n\nAnti-aggregants\n\nNSAIDS\n\nSelective serotonin reuptake inhibitors\n\nCorticosteroids (ulcers, vascular fragility)\n|Increased INR\n\n- Albumin-binding drugs (antibiotics, morphine, NSAIDs, statins, fibrates, azoles, paracetamol 4g/d, etc.), corticoids, etc.\n\n- Cytochrome inhibition: allopurinol, cimetidine, amiodoraone, ris\u00e9ofulvine, levothyroxine\n\n'''Decrease in INR:'''\n\n'''Cytochrome inducers'''\n\n- St John's Wort\n\n- Azathioprine\n\n- Anticonvulsants\n\n- protease inhibitor\n\n- Rifampicin\n<br />\n|In practice, have an INR performed 2-3 days after any change in the prescription.\n|}\n\n==Surveillance methods==\n\n====Clinical surveillance====\n\n*Compliance (particularly for AODs)\n*Tolerance: sign of bleeding\n*Effectiveness: sign of thrombosis depending on the indication\n\n====Biological monitoring====\n\n=====AOD=====\n\n*Renal function (creatinine)\n*Liver function (ASAT, ALAT, gammaGT)\n\n=====AVK=====\n\n*INR (at least once a month)\n*Renal function (creatinine and GFR calculation) if fluindione is co-prescribed or prescribed.\n*Liver function (ASAT, ALAT, gammaGT)\n*Biological tolerance is assessed on the haemogram (to check for anaemia).\n\n==Main causes of failure==\nIn decreasing order of frequency, factors influencing recurrence or the occurrence of thrombosis:\n\n*Limited benefit of anticoagulants (incomplete reduction in the risk of thrombosis, particularly in AF and prevention in orthopaedic settings).\n*Monitoring (particularly for AODs), often overestimated (AOD dosage possible).\n*Drug interactions (e.g. enzyme inducers)\n*Other mechanisms (e.g. dissection in stroke)\n*Major thrombophilia (antiphospholipid antibody syndrome, paraneoplastic thrombosis)\n*Diagnostic error",
  "question": {
    "question": "Which of the following is NOT a major drug interaction concern for Apixaban?",
    "option_a": "Enzyme inducers like rifampicin",
    "option_b": "P-glycoprotein inhibitors like amiodarone",
    "option_c": "Cytochrome CYP450 inhibitors like cimetidine",
    "option_d": "Anti-aggregants like NSAIDs",
    "correct_option": "D"
  }
}